tiprankstipranks
Trending News
More News >
China Tian Yuan Healthcare Group Limited (HK:0557)
:0557
Hong Kong Market
Advertisement

China Tian Yuan Healthcare Group Limited (0557) AI Stock Analysis

Compare
1 Followers

Top Page

HK:0557

China Tian Yuan Healthcare Group Limited

(0557)

Rating:49Neutral
Price Target:
HK$1.00
▲(26.58%Upside)
The stock's overall score is primarily impacted by significant financial challenges and poor valuation metrics. While technical analysis shows a positive trend, it is insufficient to offset the negative financial performance and valuation concerns.

China Tian Yuan Healthcare Group Limited (0557) vs. iShares MSCI Hong Kong ETF (EWH)

China Tian Yuan Healthcare Group Limited Business Overview & Revenue Model

Company DescriptionChina Tian Yuan Healthcare Group Limited (0557) is a diversified investment holding company primarily engaged in healthcare and related services. The company operates through various segments including healthcare services, medical equipment distribution, and related investment activities. It aims to integrate healthcare resources and expand its presence in the healthcare sector across the region.
How the Company Makes MoneyThe company generates revenue through multiple streams, primarily focusing on healthcare services and the distribution of medical equipment. This includes income from hospital operations, diagnostic services, and the sale of medical devices. Additionally, the company engages in strategic investments and partnerships within the healthcare industry to enhance its service offerings and drive growth. Key revenue contributors include service fees from healthcare facilities, sales of medical products, and returns on healthcare-related investments.

China Tian Yuan Healthcare Group Limited Financial Statement Overview

Summary
The company is facing significant financial challenges with declining revenues and persistent losses impacting profitability. The balance sheet is stable with a strong equity position, but cash flow improvements are overshadowed by volatility and past inefficiencies.
Income Statement
38
Negative
The company has seen a consistent decline in revenue over the years, with significant negative figures in EBIT and net income indicating ongoing profitability issues. Gross profit margin is high but overshadowed by persistent losses, suggesting challenges in controlling operating expenses.
Balance Sheet
45
Neutral
The company's debt-to-equity ratio is relatively low, indicating conservative leverage. However, the significant decline in stockholders' equity due to consistent losses raises concerns. The equity ratio remains strong, showing a robust capital structure despite financial challenges.
Cash Flow
55
Neutral
Positive operating cash flow in recent years is a positive sign, suggesting some operational efficiency. However, free cash flow has been volatile, and prior negative figures highlight potential issues in managing cash effectively. Improvement in free cash flow is notable but needs sustainability.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue26.84M45.23M54.22M94.59M56.34M
Gross Profit14.91M25.16M34.83M71.31M37.57M
EBITDA-27.22M-15.79M-27.10M-2.89M-102.72M
Net Income-34.24M-15.48M-38.45M-22.12M-110.03M
Balance Sheet
Total Assets260.93M302.95M333.55M376.40M381.30M
Cash, Cash Equivalents and Short-Term Investments27.05M26.73M31.60M77.89M71.08M
Total Debt40.93M45.91M51.13M59.66M55.06M
Total Liabilities84.98M87.77M91.52M92.35M83.91M
Stockholders Equity194.68M230.26M224.30M256.25M267.53M
Cash Flow
Free Cash Flow10.67M4.51M-31.71M14.86M49.20M
Operating Cash Flow10.69M5.10M-30.36M16.32M49.54M
Investing Cash Flow-3.00K364.00K-1.23M-1.42M-11.22M
Financing Cash Flow-10.85M-8.77M-12.49M-7.22M-2.54M

China Tian Yuan Healthcare Group Limited Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.79
Price Trends
50DMA
0.81
Negative
100DMA
0.71
Positive
200DMA
0.64
Positive
Market Momentum
MACD
>-0.01
Positive
RSI
46.53
Neutral
STOCH
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0557, the sentiment is Neutral. The current price of 0.79 is below the 20-day moving average (MA) of 0.82, below the 50-day MA of 0.81, and above the 200-day MA of 0.64, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.53 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0557.

China Tian Yuan Healthcare Group Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
HK$17.07B6.10-7.44%2.88%11.55%-28.15%
49
Neutral
HK$315.19M-16.11%-40.65%-121.13%
46
Neutral
HK$312.08M-4.04%12.86%-297.41%
44
Neutral
HK$334.38M-18.37%-2.69%-53.59%
44
Neutral
HK$198.68M-31.95%-70.49%-129.16%
43
Neutral
HK$207.20M-17.37%-3.54%-49.42%
35
Underperform
€539.27M-36.48%1.87%-42.24%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0557
China Tian Yuan Healthcare Group Limited
0.79
-0.01
-1.25%
HK:0199
ITC Properties Group Limited
0.22
-0.18
-45.00%
HK:0617
Paliburg Holdings Limited
0.30
-0.51
-62.96%
HK:0355
Century City International Holdings Limited
0.07
-0.11
-62.36%
HK:0219
Shun Ho Property Investments Ltd
0.62
-0.15
-19.48%
HK:0078
Regal Hotels International Holdings Limited
0.59
-2.30
-79.58%

China Tian Yuan Healthcare Group Limited Corporate Events

China Tian Yuan Healthcare Group Announces Capital Injections and Shareholder Loan
Jul 21, 2025

China Tian Yuan Healthcare Group Limited announced capital injections and a shareholder loan involving its subsidiaries, Hengqin Hanyuemei and Shanghai Rifu, and a third party, Shanghai Huaman. The capital injections will increase Shanghai Rifu’s registered capital significantly, while the shareholder loan will provide additional financial support. These transactions, which are part of a series of agreements with Shanghai Huaman, are subject to disclosure requirements under Hong Kong’s listing rules due to their size.

China Tian Yuan Healthcare Group Secures Unanimous Shareholder Approval at AGM
Jun 27, 2025

China Tian Yuan Healthcare Group Limited announced that all resolutions proposed at their Annual General Meeting on June 27, 2025, were unanimously approved by shareholders. These resolutions included the re-election of directors, authorization of directors’ remuneration, reappointment of auditors, and granting of general mandates for issuing and repurchasing shares, indicating strong shareholder support and stability in the company’s governance and operational strategies.

China Tian Yuan Healthcare Group Announces 36th Annual General Meeting
May 23, 2025

China Tian Yuan Healthcare Group Limited has announced its thirty-sixth annual general meeting to be held on June 27, 2025, in Hong Kong. Key agenda items include the re-election of directors, approval of directors’ remuneration, and the re-appointment of auditors. Additionally, the company seeks approval to allot and issue additional shares, which could impact its capital structure and shareholder value.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 16, 2025